Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts (Q46661656)

24 December 2017

title

Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts (English)

1 reference

24 December 2017

Waldmann H

1 reference

24 December 2017

Geoff Hale

series ordinal

object named as

Hale G

1 reference

24 December 2017

author name string

Novitzky N

series ordinal

1 reference

24 December 2017

Thomas V

series ordinal

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

24 December 2017

Bone Marrow Transplantation

published in

1 reference

24 December 2017

volume

1 reference

24 December 2017

issue

1 reference

24 December 2017

page(s)

675-682

1 reference

24 December 2017

Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Infectious complications following T-cell depleted hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell se

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell tra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

Allogeneic myeloablative transplantation for patients aged 50 years and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Risk factors for early mortality in allogeneic bone marrow transplantation. A multivariate analysis on 174 leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

EX VIVO DEPLETION OF T CELLS FROM BONE MARROW GRAFTS WITH CAMPATH-1 IN ACUTE LEUKEMIA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Manufacture and quality control of CAMPATH-1 antibodies for clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

IMMUNE RECONSTITUTION AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION DEPLETED OF T CELLS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705119

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705119

1 reference

24 December 2017

Dimensions Publication ID

1013225357

0 references

1 reference

24 December 2017